CN120380345A - 判定认知功能障碍阶段的方法 - Google Patents

判定认知功能障碍阶段的方法

Info

Publication number
CN120380345A
CN120380345A CN202380082792.9A CN202380082792A CN120380345A CN 120380345 A CN120380345 A CN 120380345A CN 202380082792 A CN202380082792 A CN 202380082792A CN 120380345 A CN120380345 A CN 120380345A
Authority
CN
China
Prior art keywords
level
amount
protein
subject
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380082792.9A
Other languages
English (en)
Chinese (zh)
Inventor
白尾智明
关野祐子
东海林干夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almeide Co
Original Assignee
Almeide Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almeide Co filed Critical Almeide Co
Publication of CN120380345A publication Critical patent/CN120380345A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN202380082792.9A 2022-12-05 2023-12-01 判定认知功能障碍阶段的方法 Pending CN120380345A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022194368 2022-12-05
JP2022-194368 2022-12-05
PCT/JP2023/043089 WO2024122459A1 (ja) 2022-12-05 2023-12-01 認知機能障害ステージを判定する方法

Publications (1)

Publication Number Publication Date
CN120380345A true CN120380345A (zh) 2025-07-25

Family

ID=91379188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380082792.9A Pending CN120380345A (zh) 2022-12-05 2023-12-01 判定认知功能障碍阶段的方法

Country Status (4)

Country Link
EP (1) EP4632384A1 (https=)
JP (1) JPWO2024122459A1 (https=)
CN (1) CN120380345A (https=)
WO (1) WO2024122459A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025177848A1 (ja) * 2024-02-22 2025-08-28 アルメッド株式会社 ドレブリン由来のｉＭＡＤＰ、ｉＭＡＤＰを測定する方法及びｉＭＡＤＰの測定用キット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016040540A (ja) 2014-08-13 2016-03-24 国立大学法人群馬大学 ドレブリンａ及びドレブリンｅの特異的定量法
JP7324994B2 (ja) * 2018-05-08 2023-08-14 アルメッド株式会社 ドレブリンに特異的に結合するペプチド、及びそのペプチドを用いたドレブリンの検出方法
CN115176163B (zh) * 2019-11-29 2026-03-24 富士胶片和光纯药株式会社 辅助阿尔茨海默型痴呆症或轻度认知障碍的诊断的方法、生物标志物、试剂盒及装置
JP7244931B2 (ja) * 2020-06-19 2023-03-23 アルメッド株式会社 シナプス機能不全に起因する、又はシナプス機能不全を付随する疾病の判定方法
WO2022070798A1 (ja) * 2020-09-29 2022-04-07 康弘 橋本 アルツハイマー病病態鑑別用組み合わせマーカー及びそれを用いたアルツハイマー病病態鑑別方法
US20240142471A1 (en) * 2021-02-26 2024-05-02 Osaka University Test for mild cognitive impairment

Also Published As

Publication number Publication date
WO2024122459A9 (ja) 2024-08-02
JPWO2024122459A1 (https=) 2024-06-13
WO2024122459A1 (ja) 2024-06-13
EP4632384A1 (en) 2025-10-15

Similar Documents

Publication Publication Date Title
Ashton et al. An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders
Piubelli et al. Serum D-serine levels are altered in early phases of Alzheimer’s disease: towards a precocious biomarker
US20230243853A1 (en) Method of identifying biomarkers of neurological diseases and diagnosis of neurological diseases
Bereczki et al. Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
An et al. Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42
Korolainen et al. Oxidative modification of proteins in the frontal cortex of Alzheimer's disease brain
KR102130929B1 (ko) 뇌의 베타 아밀로이드 축적 감별용 혈중 lgals3bp 바이오마커
Feneberg et al. Detection and quantification of novel C‐terminal TDP‐43 fragments in ALS‐TDP
Serafín et al. Enlightening the advancements in electrochemical bioanalysis for the diagnosis of Alzheimer’s disease and other neurodegenerative disorders
EP3452830B1 (en) Assay for the diagnosis of a neurological disease
EP3633372A1 (en) Biomarker for alzheimer's disease
EP2031398B1 (en) Alzheimer's disease-specific alterations of the ERK1/ERK2 phosphorylation ratio as Alzheimer's disease-specific molecular biomarkers (ADSMB)
Saunders et al. Predictive blood biomarkers and brain changes associated with age-related cognitive decline
KR20210127145A (ko) 다중 분석 및 이의 사용 방법
Ghidoni et al. Translational proteomics in Alzheimer's disease and related disorders
US20250138029A1 (en) Methods for assessing likelihood of post-operative delirium in patients undergoing surgery
CN120380345A (zh) 判定认知功能障碍阶段的方法
WO2021009074A1 (en) Novel markers as early predictors of alzheimer's pathology
EP3872494A1 (en) Blood biomarker for detecting deposition of amyloid beta in brains of groups with normal cognitive function and mild cognitive impairment
EP1934618B1 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
US20130184173A1 (en) Biomarkers for multiple sclerosis
Jamerlan et al. Current status of fluid biomarkers for early Alzheimer's disease and FDA regulation implications
US20250306037A1 (en) Methods to detect ab proteoforms and use thereof
US20220308073A1 (en) Biomarker for alzheimer's disease
US20240345101A1 (en) Methods for diagnosis and prognosis of alzheimer's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination